Burning Rock Biotech (NASDAQ:BNR) Stock Price Down 1.3% – What’s Next?

Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR) shares fell 1.3% during mid-day trading on Thursday . The stock traded as low as $20.36 and last traded at $20.59. 24,167 shares changed hands during trading, a decline of 23% from the average session volume of 31,464 shares. The stock had previously closed at $20.86.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on BNR. Weiss Ratings reissued a “sell (d-)” rating on shares of Burning Rock Biotech in a research report on Monday. Wall Street Zen upgraded shares of Burning Rock Biotech from a “hold” rating to a “buy” rating in a research note on Saturday, January 17th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has a consensus rating of “Sell”.

Burning Rock Biotech Stock Performance

The firm’s 50-day moving average is $21.26 and its 200 day moving average is $20.42. The stock has a market cap of $221.55 million, a PE ratio of -26.06 and a beta of 1.59.

Burning Rock Biotech (NASDAQ:BNR) last posted its quarterly earnings data on Saturday, February 14th. The company reported ($0.21) earnings per share for the quarter. Burning Rock Biotech had a negative net margin of 10.27% and a negative return on equity of 9.98%. The firm had revenue of $18.05 million during the quarter.

Insider Buying and Selling

In related news, Director Yusheng Han acquired 314,870 shares of the company’s stock in a transaction that occurred on Tuesday, March 31st. The stock was purchased at an average price of $17.36 per share, for a total transaction of $5,466,143.20. Following the transaction, the director owned 17,672,676 shares in the company, valued at $306,797,655.36. This trade represents a 1.81% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 30.30% of the company’s stock.

Institutional Trading of Burning Rock Biotech

Institutional investors have recently modified their holdings of the company. Crcm LP grew its holdings in shares of Burning Rock Biotech by 13.8% during the 3rd quarter. Crcm LP now owns 221,575 shares of the company’s stock worth $1,917,000 after purchasing an additional 26,809 shares during the period. Prospera Financial Services Inc acquired a new position in shares of Burning Rock Biotech in the 3rd quarter valued at approximately $214,000. Marshall Wace LLP acquired a new position in shares of Burning Rock Biotech in the 4th quarter valued at approximately $220,000. Finally, China Universal Asset Management Co. Ltd. bought a new stake in shares of Burning Rock Biotech in the 3rd quarter valued at approximately $26,000. Hedge funds and other institutional investors own 30.03% of the company’s stock.

Burning Rock Biotech Company Profile

Burning Rock Biotech (NASDAQ: BNR) is a precision oncology company specializing in the development and commercialization of next-generation sequencing (NGS)–based cancer diagnostics. The company’s core business revolves around liquid biopsy tests, which analyze circulating tumor DNA (ctDNA) from blood samples to detect genetic mutations associated with various solid tumors. By enabling noninvasive profiling of tumor genomics, Burning Rock Biotech aims to guide personalized therapy decisions and monitor treatment response in cancer patients.

Founded in 2014 and headquartered in Guangzhou, China, Burning Rock Biotech launched its first clinical services in the mid-2010s and subsequently expanded its laboratory network across major Chinese cities.